Loss of both the wild-type Kras allele and the adjacent Cas9 allele may be selected for during sarcomagenesis because the wild-type Kras allele can act as a tumour suppressor in the presence of an oncogenic Kras that drives transformation and tumorigenesis28, 29, 30. The gene discussed is KRAS; the disease is neoplasm.